Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 31;5(7):870-875.
doi: 10.1002/acn3.580. eCollection 2018 Jul.

Immunosuppressants and risk of Parkinson disease

Brad A Racette  1   2 , Anat Gross  1 , Scott Martin Vouri  3 , Alejandra Camacho-Soto  1 , Allison W Willis  4   5   6 , Susan Searles Nielsen  1
Affiliations

Immunosuppressants and risk of Parkinson disease

Brad A Racette et al. Ann Clin Transl Neurol. .

Abstract

We performed a population-based case-control study of United States Medicare beneficiaries age 60-90 in 2009 with prescription data (48,295 incident Parkinson disease cases and 52,324 controls) to examine the risk of Parkinson disease in relation to use of immunosuppressants. Inosine monophosphate dehydrogenase inhibitors (relative risk = 0.64; 95% confidence interval 0.51-0.79) and corticosteroids (relative risk = 0.80; 95% confidence interval 0.77-0.83) were both associated with a lower risk of Parkinson disease. Inverse associations for both remained after applying a 12-month exposure lag. Overall, this study provides evidence that use of corticosteroids and inosine monophosphate dehydrogenase inhibitors might lower the risk of Parkinson disease.

PubMed Disclaimer

References

    1. Parkinson Study Group PRECEPT Investigators . Mixed lineage kinase inhibitor CEP‐1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480–1490. - PubMed
    1. Parkinson Study Group . Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176–183. - PubMed
    1. Olanow CW, Rascol O, Hauser R, et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268–1278. - PubMed
    1. Olanow CW, Goetz CG, Kordower JH, et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403–414. - PubMed
    1. Kieburtz K, Tilley BC, Elm JJ, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 2015;313:584–593. - PMC - PubMed